Angioimmunoblastic
T-Cell Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Some drugs that are used for other lymphomas may at times be considered for use in patients with angioimmunoblastic T-cell lymphoma (AITL) that has relapsed or is refractory to other treatments, including:
- Alemtuzumab (Campath)
- Bendamustine (Treanda)
- Bortezomib (Velcade)
- Cyclosporine
- Fludarabine (Fludara)
- Gemcitabine (Gemzar)
- Pralatrexate (Folotyn)
- Rituximab (Rituxan)
- Romidepsin (Istodax)
- Belinostat (Beleodaq)
Learn More
To learn more about AITL, download the Angioimmunoblastic T-Cell Lymphoma Fact Sheet. Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Helpline at (800) 500-9976 or helpline@lymphoma.org.

Additional Resources
To learn more about ATLL, download the Adult T-Cell Leukemia/Lymphoma Fact Sheet.
Events
Ask the Doctor: Information for Newly Diagnosed Patients
VirtualThis program provides newly diagnosed patients with a strong foundation to begin their patient journey. […]
Understanding Immunotherapy for Lymphoma Webinar
VirtualProgram Overview:
Ask the Doctor: Information for Relapsed/Refractory Patients
VirtualAsk the Doctor About Lymphoma is a virtual two-hour program that combines a comprehensive and […]